Roche chose Germany to transfer UK-based licences and trialsRoche has chosen Germany to transfer all licences and clinical trials initially registered in the UK in preparation for the UK leaving the European Union, head of Roche Pharma Germany Hagen Pfundner told FAZ on Tuesday (p18) (APMHE 61831).
Medigene appoints new CFOGerman biotech Medigene has appointed Axel-Sven Malkomes as its new chief finance officer from 1 April, FAZ reported on Tuesday (p20).
Gaps remain in EU anti-counterfeit systemThe EU anti-counterfeit system, started last weekend, has important gaps that put into question its efficacy, FAZ on Saturday (p17 and 21).
J&J's nasal spray Spravato for depression backed by FDA panelAdvisers to the U.S. Food and Drug Administration have voted in favour of Johnson & Johnson's experimental nasal spray Spravato (eketamine) for treatment-resistant depression, Die Welt reports on Friday (p9) (APMHE 61843).
Statins too often recommended in guidelinesSwiss epidemiologist Milo Puham has published a review of statins in primary stroke prevention in the Annals of Internal Medicine, saying that cardiology guidelines are recommending statin therapy far too often, Die Welt reports on Friday (p20).
Harvard professor gained $400 million through Moderna's IPOHarvard professor Timothy Springer might have become the richest U.S. scientist after receiving shares of worth $400 million when Massachusetts-based biotech Moderna Therapeutics went public in December 2018, Sueddeutsche Zeitung (SZ) reported in a portrait published on Monday (p17).
Melatonin available as prescription drug and dietary supplement in GermanyWhile Lundbeck's Circadin is the only prescription melatonin drug that is approved in Europe, other melatonin products are available for German patients as dietary supplements in drugstores or online pharmacies, Die Welt reported on Tuesday (p20) and FAZ on Wednesday (p29).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.